Predicting and diagnosing patients with autoimmune disease

Details Predicting and diagnosing patients with autoimmune disease Predicting and diagnosing patients with autoimmune disease

2011-08-30

2011-08-30

Salmon, Katherine (Department: 1634)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091100, C436S063000

Reexamination Certificate

active

08008013

ABSTRACT:
The present invention provides methods for the prediction and diagnosis of autoimmune diseases, including Systemic Lupus Erythematosus, using single nucleotide polymorphism in TNFAIP3 (A20).

REFERENCES:
patent: 7259179 (2007-08-01), Burns et al.
patent: 7262199 (2007-08-01), Fraley et al.
patent: 7265134 (2007-09-01), Hartman et al.
patent: 7276581 (2007-10-01), Yeatman et al.
patent: 7279469 (2007-10-01), Pierce et al.
patent: 7282504 (2007-10-01), Armistead et al.
patent: 2003/0171253 (2003-09-01), Ma et al.
patent: WO 2008/041953 (2008-04-01), None
Dieguez-Gonzalez et al. (Arthritis Research and Therapy 2009 vol. 11 p. 42).
Halushka (Nature Genetics, 1999; 22:239-247).
Langdahl (Journal of Bone and Mineral Research 2000 vol. 15 p. 402).
Wall (Nature Reviews Genetics 2003 vol. 4, pp. 587-597).
Musone et al. (Nature 2008 vol. 40 p. 1062).
Baechler et al., “Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus,”PNAS, 100:2610-2615, 2003.
Beyaert et al., “A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis,”Biochem. Pharmacol., 60:1143-1151, 2000.
Boone et al., “The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses,”Nat. Immunol. 5:1052-1060,2004.
Durkop et al., “Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation,”J. Path., 200:229-239, 2003.
Ferretti et al., “PReMod: a database of genome-wide mammalian cis-regulatory module predictions,”Nucleic Acids Res., 35:D122-D126, 2007.
Fung et al., “Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus,”Genes and Immunity, 1-4, 2008.
Gaffney et al., “Fine-mapping chromosome 20 in 230 systemic lupus erythematosus sib pair and multiplex families: evidence for genetic epistasis with chromosome 16q12,”Am. J. Hum. Genet., 78:747-758, 2006.
Gaffney et al., “A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families,”PNAS, 95:14875-14879, 1998.
Gaffney, “Genome screening in human systemic lupus erythematosus: results from a second Minnesota cohort and combined analyses of 187 sib-pair families,”Am. J. Hum. Genet., 66:547-556, 2000.
Graham et al., “Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus,”Nature Genetics, 40:1059-1061, 2008.
Grey et al., “Adenovirus-mediated gene transfer of A20 in murine islets inhibits Fas-induced apoptosis,”Transplant Proc., 33:577-578, 2001.
Grey et al., “Genetic engineering of a suboptimal islet graft with A20 preserves beta cell mass and function,”J. Immunol., 170:6250-6256,2003.
Harley et al., “The genetics of human systemic lupus erythematosus,”Current Opinions in Immunology, 10:690-696, 1998.
He and Ting, “A20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells,”Mol. Cell Biol., 22:3034-3045, 2002.
Heyninck and Beyaert, “The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level of TRAF6,”FEBS Lett., 442:147-150, 1999.
Heyninck and Beyaert, “A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions,”Trends Biochem. Sci., 30:1-4, 2005.
Heyninck, “The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN,”J. Cell Biol., 145:1471-1482, 1999.
Jarvis et al., “Human cytomegalovirus attenuates interleukin-1 beta and tumor necrosis factor alpha proinflammatory signaling by inhibition of NF-kappaB activation,”J. Virol., 80:5588-5598, 2006.
Liuwantara et al., “Nuclear factor-kappaB regulates beta-cell death: a critical role for A20 in beta-cell protection,”Diabetes, 55:2491-2501, 2006.
Moser et al., “Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees,”PNAS, 95:14869-14874, 1998.
Musone et al., “Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus,”Nat. Genet., 40:1062-1064, 2008.
NCBI Accession No. NM—006290.2,Homo sapienstumor necrosis factor, alpha-induced protein 3 (TNFAIP3), mRNA, 1990.
NCBI Accession No. NP—006281.1, Tumor necrosis factor, alpha-induced protein 3 [Homo Sapiens], 1990.
Plenge et al., “Two independent alleles at 6q23 associated with risk of rheumatoid arthritis,”Nature Genetics, 39:1477-1482, 2007.
Ramensky et al., “Human non-synonymous SNPs: server and survey,”Nucleic Acid Res., 30:3894-3900, 2002.
Song et al., “The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation,”PNAS, 93:6721-6725, 1996.
Thomson et al., “Rheumatoid arthritis association at 6q23,”Nature Genetics, 39:1431-1433, 2007.
Wellcome Trust Case Control Consortium, “Genome-wide association study of 14,000 cases of seven common disease and 3,000 shared controls,”Nature, 447:661-678, 2007.
Wertz et al., “De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling,”Nature, 430:694-699, 2004.
Idel et al., “A20, a regulator of NFκB, maps to an atherosclerosis locus and differs between parental sensitive C577BL/6J and resistant FVB/N strains,”PNAS, 100:14235-14240, 2003.
Boonyasrisawat et al., “Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes,”Diabetes, 56:499-505, 2007.
Gaffney et al., “Recent advances in the genetics of systemic lupus erythematosus,”Rheumatic Disease Clinics of North America, 28:111-126, 2002.
Graham et al., “A genome-wide association scan identifies tumor necrosis factor alpha inducible protein 3 (TNFAIP3/A20) as a susceptibility locus for systemic lupus erythematosus,”Arthritis&Rheumatism, 58 (Suppl. S.):S621-S622, Abstract # 1218, 2008.
Idel et al., “A20, a regulator of NFκB, maps to an atherosclerosis locus and differs between parental sensitive C577BL/6J and resistant FVB/N strains,”PNAS, 100:14235-14240, 2003.
Kyogoku et al., “Genetic association if the R620W polymorphism of protein tyrosine phosphate PTPN22 with human SLE,”Am. J. Hum. Genet., 75:504-507, 2004.
Lessard et al., “Imputation and meta-analysis define a similar to 100 kb risk haplotype spanning TNFAIP3 associated with SLE,”Arthritis&Rheumatism, 58 (Suppl. S): S219, Abstract # 140, 2008.
Luettich et al., “Global gene expression analysis identifies a novel apoptotic pathway in cutaneous lupus erythematosus,”J. Invest. Dermat., vol. 121, Abstract # 0113, 2003.
Musone et al., “Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus,”Arthritis&Rheumatism, 58 (Suppl. S):S622, Abstract # 1219, 2008.

Affiliated with

Also associated with

Rating

Predicting and diagnosing patients with autoimmune disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Predicting and diagnosing patients with autoimmune disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Predicting and diagnosing patients with autoimmune disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2704818